ArticleJCI insight2018
Age-related tumor growth in mice is related to integrin α 4 in CD8+ T cells.
Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Stem cells as an essential mediator of the exercise-tumorigenesis link.Nature reviews. Cancer · 2026Review
- Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025Review
- Lymphoma accelerates T cell and tissue aging.Cancer cell · 2025Article
- Immunosenescence: signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Timely administration of drug combination improves chemoimmunotherapy of an immune-cold tumor.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy.Translational lung cancer research · 2025Article
- Single-Cell Profiling Reveals Global Immune Responses During the Progression of Murine Epidermal Neoplasms.Cancers · 2025Article
- Fluorinated Ribonucleocarbohydrate Nanoparticles Allow Ultraefficient mRNA Delivery and Protein Expression in Tumor-Associated Myeloid Cells.Journal of the American Chemical Society · 2025Article
- Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.International journal of biological sciences · 2025Review
- Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity.Cancer immunology research · 2024Article
- Anti-CD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8Journal of neuroinflammation · 2024Article
- TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.Neuro-oncology · 2024Article
- Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment.Nature communications · 2024Article
- Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications.Biomedicines · 2024Review
- Design and Pharmacological Characterization of αJournal of medicinal chemistry · 2023Article
- TREM2 mediates MHCII-associated CD4bioRxiv : the preprint server for biology · 2023Article
- Age-associated remodeling of T cell immunity and metabolism.Cell metabolism · 2023Review
- Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.Frontiers in endocrinology · 2023Article
- Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.Frontiers in immunology · 2023Article
- Single-Cell RNA Sequencing Reveals Heterogeneity in the Tumor Microenvironment between Young-Onset and Old-Onset Colorectal Cancer.Biomolecules · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Cancer incidence increases with age, but paradoxically, cancers have been found to grow more quickly in young mice compared with aged ones. The cause of differential tumor growth has been debated and, over time, attributed to faster tumor cell proliferation, decreased tumor cell apoptosis, and/or increased angiogenesis in young animals. Despite major advances in our understanding of tumor immunity over the past 2 decades, little attention has been paid to comparing immune cell populations in young and aged mice. Using mouse colon adenocarcinoma model MC38 implanted in young and mature mice, we show that age substantially influences the number of tumor-infiltrating cytotoxic CD8+ T cells, which control cancer progression. The different tumor growth pace in young and mature mice was abrogated in RAG1null mice, which lack mature T and B lymphocytes, and upon selective depletion of endogenous CD8+ cells. Transcriptome analysis further indicated that young mice have decreased levels of the Itga4 gene (CD49d, VLA-4) in tumor-infiltrating lymphocytes when compared with mature mice. Hypothesizing that VLA-4 can have a tumor-protective effect, we depleted the protein, which resulted in accelerated tumor growth in mature mice. These observations may explain the paradoxical growth rates observed in murine cancers, point to the central role of VLA-4 in controlling tumor growth, and open new venues to therapeutic manipulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.